IL282122A - Antibody variants and uses thereof - Google Patents

Antibody variants and uses thereof

Info

Publication number
IL282122A
IL282122A IL282122A IL28212221A IL282122A IL 282122 A IL282122 A IL 282122A IL 282122 A IL282122 A IL 282122A IL 28212221 A IL28212221 A IL 28212221A IL 282122 A IL282122 A IL 282122A
Authority
IL
Israel
Prior art keywords
mutation
variant
domain
parent polypeptide
antibody variants
Prior art date
Application number
IL282122A
Other languages
Hebrew (he)
Original Assignee
Genmab Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/063339 external-priority patent/WO2013004842A2/en
Application filed by Genmab Bv filed Critical Genmab Bv
Publication of IL282122A publication Critical patent/IL282122A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

To provide polypeptides and related antibodies comprising a variant Fc domain.SOLUTION: The present invention provides a method of increasing an effector function of a parent polypeptide comprising an Fc-domain of an immunoglobulin and a binding region, the method comprising introducing a mutation to the parent polypeptide in at least one amino acid residue selected from those corresponding to E345, E430, S440, Q386, P247, I253, S254, Q311, D/E356, T359, E382, Y436, and K447 in the Fc-region of a human IgG1 heavy chain, with the proviso that the mutation in S440 is S440Y or S440W; a variant and composition thereof.SELECTED DRAWING: None
IL282122A 2011-07-06 2021-04-07 Antibody variants and uses thereof IL282122A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161504994P 2011-07-06 2011-07-06
DKPA201100519 2011-07-06
DKPA201200371 2012-05-30
PCT/EP2012/063339 WO2013004842A2 (en) 2011-07-06 2012-07-06 Antibody variants and uses thereof

Publications (1)

Publication Number Publication Date
IL282122A true IL282122A (en) 2021-05-31

Family

ID=67997265

Family Applications (2)

Application Number Title Priority Date Filing Date
IL230098A IL230098B (en) 2011-07-06 2013-12-23 Antibody variants and uses thereof
IL282122A IL282122A (en) 2011-07-06 2021-04-07 Antibody variants and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL230098A IL230098B (en) 2011-07-06 2013-12-23 Antibody variants and uses thereof

Country Status (4)

Country Link
JP (2) JP2020055800A (en)
KR (1) KR20200120743A (en)
IL (2) IL230098B (en)
ZA (1) ZA201608707B (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375365T1 (en) * 1998-04-02 2007-10-15 Genentech Inc ANTIBODIES VARIANTS AND FRAGMENTS THEREOF
WO2005047327A2 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
DE602005015542D1 (en) * 2004-01-12 2009-09-03 Applied Molecular Evolution VARIANTS OF FC REGION
US20100104564A1 (en) * 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
EP2087111A2 (en) * 2007-03-19 2009-08-12 Medimmune Limited Polypeptide variants
EP3524620A1 (en) * 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
EA201201435A1 (en) * 2010-04-20 2013-04-30 Генмаб А/С HETERODIMERNY ANTIBODY-Fc-CONTAINING PROTEINS AND METHODS FOR THEIR RECEIVING
UA117901C2 (en) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Antibody variants and uses thereof

Also Published As

Publication number Publication date
JP2020055800A (en) 2020-04-09
ZA201608707B (en) 2019-09-25
KR20200120743A (en) 2020-10-21
JP2021120385A (en) 2021-08-19
IL230098B (en) 2021-06-30

Similar Documents

Publication Publication Date Title
WO2013011076A3 (en) Tnf -alpha antigen- binding proteins with increased fcrn binding
RU2013140350A (en) ANTIBODIES AGAINST HUMAN IL33R AND THEIR APPLICATION
IN2015DN01361A (en)
EA201290413A1 (en) MUTATED Fc ANTIBODIES WITH ELIMINATED EFFECTOR FUNCTIONS
EA201390923A1 (en) MODIFIED ANTIBODY WITH AN IMPROVED ELEMENTATION SEMIUM PERIOD
WO2009131702A3 (en) Antibodies against fcrn and use thereof
NZ701444A (en) Antibodies to matrix metalloproteinase 9
EA201190132A1 (en) HUMANIZED ANTIBODIES, CONNECTING CD19, AND THEIR APPLICATION
EA201490745A1 (en) POLYPEPTIDES OF ANTIBODIES THAT CAUSE ANTAGONISM CD40L
EA201591407A1 (en) ANTIBODIES CONTAINING CHEMICAL CONSTANT DOMAINS
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
WO2009048537A3 (en) Humanized antibody
CA2953714C (en) Anti-tnfa antibodies with ph-dependent antigen binding
WO2012016073A3 (en) Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
TR201815254T4 (en) ANTIBODIES CONNECTED TO TL1A AND THEIR USES
UA117901C2 (en) Antibody variants and uses thereof
RU2013140625A (en) ANTIBODIES AGAINST HUMAN ANGIOPOETIN-2
CR20120359A (en) ANTI-IL-10 HUMANIZED ANTIBODIES FOR THE TREATMENT OF ERYTHEMATE SYSTEM LUPUS (SLE)
BR112014027659A2 (en) cll-1 specific antibodies
EA201391761A1 (en) ANTI-ALPHA-SINUCLAIN-BINDING MOLECULES
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
NZ707327A (en) Mice that make binding proteins comprising vl domains
WO2012156532A8 (en) Anti-human-her3 antibodies and uses thereof
MX2010006767A (en) Hepatitis c virus antibodies.
EA201790816A1 (en) ANTIBODIES THAT ARE ASSOCIATED WITH CCR6 AND APPLICATION OPTIONS FOR THE INDICATED ANTIBODIES